Abbott Laboratories Corporation

Robert J Carrick

Tami J Pilot-Matias

Rolf Wagner

Todd Warren Rockway

David A Betebenner

Rong Zhang

Curt S Cooper

David D Anderson

Liangjun Lu

Wenping He

Hongmei Mo

Dale J Kempf

Allan C Krueger

Michael D Tufano

Christopher E Motter

Darold L Madigan

Jason P Shanley

Sherie V L Masse

Akhteruzzaman Molla

Nobuhiko Iwasaki

Clarence J Maring

John K Pratt

Dachun Liu

David A DeGoey

Keith F McDaniel

Pamela L Donner

David J Grampovnik

Brian E Green

Suresh M Desai

George J Dawson

Anthony Scott Muerhoff

Isa K Mushahwar

Thomas P Leary

John N Simons

Teresa K Surowy

Sherie Vl Masse

Akteruzzaman Molla

Weping He

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Anti-viral compounds

Recombinantly produced hepatitis GB Virus (HGBV) amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV amino acid sequences and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV recombinantly produced amino acid sequences.

Hepatitis GB virus recombinant proteins and uses thereof

Growing community of inventors

Pleasant Prairie, WI, United States of America

Robert J Carrick